Key result
Pathogenic adipose tissue, characterized by adipocyte hypertrophy and visceral adiposity, acts as a disease state that interacts with other organs to promote metabolic and cardiovascular diseases.
Recognizing pathogenic adipose tissue as a disease state with systemic cross-talk may improve strategies for treating metabolic diseases and reducing cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Supports adipose assessment in cardiometabolic risk models; leaves open whether targeting visceral adiposity improves outcomes.
Bays et al. (2008) conducted a review in Metabolic disease and cardiovascular disease risk. Pathogenic adipose tissue (adipocyte hypertrophy and visceral adiposity) was evaluated. Pathogenic adipose tissue, characterized by adipocyte hypertrophy and visceral adiposity, acts as a disease state that interacts with other organs to promote metabolic and cardiovascular diseases.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: